A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia
Latest Information Update: 25 Apr 2025
At a glance
- Drugs Enlicitide decanoate (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; Registrational
- Sponsors Merck Sharp & Dohme
- 14 Aug 2024 Status changed from not yet recruiting to recruiting.
- 17 Jul 2024 New trial record